AngioDynamics, Inc. (ANGO)
NASDAQ: ANGO · Real-Time Price · USD
6.74
+0.06 (0.90%)
Nov 4, 2024, 4:00 PM EST - Market closed
AngioDynamics Employees
AngioDynamics had 748 employees as of May 31, 2024. The number of employees decreased by 67 or -8.22% compared to the previous year.
Employees
748
Change (1Y)
-67
Growth (1Y)
-8.22%
Revenue / Employee
$391,345
Profits / Employee
-$324,908
Market Cap
273.87M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| AVITA Medical | 207 |
| Vanda Pharmaceuticals | 203 |
| Fate Therapeutics | 181 |
| TScan Therapeutics | 154 |
| Heron Therapeutics | 126 |
| Atea Pharmaceuticals | 75 |
| Ocugen | 65 |
| Inozyme Pharma | 59 |
ANGO News
- 12 days ago - AngioDynamics and University College London Hospital Launch International Multi-Center Study to Assess Long Term Effects of Treatment with The NanoKnife® System - Business Wire
- 14 days ago - AngioDynamics Announces American Medical Association's CPT® Editorial Panel Grants Category I CPT® for Irreversible Electroporation (IRE) in Prostate and Liver - Business Wire
- 4 weeks ago - AngioDynamics, Inc. (ANGO) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - AngioDynamics, Ingevity, Levi Strauss And Other Big Stocks Moving Lower On Thursday - Benzinga
- 4 weeks ago - AngioDynamics Reports Fiscal Year 2025 First Quarter Financial Results - Business Wire
- 4 weeks ago - Top Wall Street Forecasters Revamp AngioDynamics Price Expectations Ahead Of Q1 Earnings - Benzinga
- 6 weeks ago - AngioDynamics Initiates RECOVER-AV Clinical Trial Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism and Long-Term Functional Outcomes - Business Wire
- 6 weeks ago - AngioDynamics to Report Fiscal 2025 First Quarter Financial Results on October 3, 2024 - Business Wire